
Richard A. Schnizer
Examiner (ID: 700, Phone: (571)272-0762 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1632, 1674 |
| Total Applications | 1559 |
| Issued Applications | 675 |
| Pending Applications | 181 |
| Abandoned Applications | 710 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15481169
[patent_doc_number] => 10555910
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-11
[patent_title] => Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 15/798815
[patent_app_country] => US
[patent_app_date] => 2017-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 60
[patent_no_of_words] => 18638
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15798815
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/798815 | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same | Oct 30, 2017 | Issued |
Array
(
[id] => 15866927
[patent_doc_number] => 20200140867
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 16/345743
[patent_app_country] => US
[patent_app_date] => 2017-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345743
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/345743 | Compositions and methods for the treatment of myotonic dystrophy | Oct 26, 2017 | Issued |
Array
(
[id] => 15035517
[patent_doc_number] => 20190328763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => A LIPID NANOPARTICLE FOR CARRYING ANTISENSE OLIGONUCLEOTIDES INHIBITING BCL-2 AND METHOD FOR PREPARING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/342871
[patent_app_country] => US
[patent_app_date] => 2017-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5509
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342871
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/342871 | A LIPID NANOPARTICLE FOR CARRYING ANTISENSE OLIGONUCLEOTIDES INHIBITING BCL-2 AND METHOD FOR PREPARING THE SAME | Oct 12, 2017 | Abandoned |
Array
(
[id] => 16177234
[patent_doc_number] => 20200224202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of CD39
[patent_app_type] => utility
[patent_app_number] => 16/340259
[patent_app_country] => US
[patent_app_date] => 2017-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340259
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/340259 | Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39 | Oct 8, 2017 | Issued |
Array
(
[id] => 18412068
[patent_doc_number] => 11666595
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/340318
[patent_app_country] => US
[patent_app_date] => 2017-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 10
[patent_no_of_words] => 11517
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340318
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/340318 | Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer | Oct 5, 2017 | Issued |
Array
(
[id] => 12641946
[patent_doc_number] => 20180105813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-04-19
[patent_title] => Treatment of Cancers with Micro-RNA Inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/724860
[patent_app_country] => US
[patent_app_date] => 2017-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15724860
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/724860 | Treatment of Cancers with Micro-RNA Inhibitors | Oct 3, 2017 | Abandoned |
Array
(
[id] => 14682459
[patent_doc_number] => 20190240344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-08
[patent_title] => FUNCTIONAL RNA AND SMALL-MOLECULE DRUG THERAPEUTIC COMPLEXES AND NANOPARTICLE DELIVERY VEHICLES
[patent_app_type] => utility
[patent_app_number] => 16/338909
[patent_app_country] => US
[patent_app_date] => 2017-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338909
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/338909 | FUNCTIONAL RNA AND SMALL-MOLECULE DRUG THERAPEUTIC COMPLEXES AND NANOPARTICLE DELIVERY VEHICLES | Oct 2, 2017 | Abandoned |
Array
(
[id] => 15432357
[patent_doc_number] => 20200030361
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/335663
[patent_app_country] => US
[patent_app_date] => 2017-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335663
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/335663 | OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES | Sep 22, 2017 | Abandoned |
Array
(
[id] => 14833541
[patent_doc_number] => 20190275171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => GENE THERAPY AND TARGETED DELIVERY OF CONJUGATED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/335171
[patent_app_country] => US
[patent_app_date] => 2017-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335171
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/335171 | GENE THERAPY AND TARGETED DELIVERY OF CONJUGATED COMPOUNDS | Sep 21, 2017 | Abandoned |
Array
(
[id] => 13251631
[patent_doc_number] => 10138497
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-11-27
[patent_title] => Agents for improved delivery of nucleic acids to eukaryotic cells
[patent_app_type] => utility
[patent_app_number] => 15/707740
[patent_app_country] => US
[patent_app_date] => 2017-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 9791
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15707740
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/707740 | Agents for improved delivery of nucleic acids to eukaryotic cells | Sep 17, 2017 | Issued |
Array
(
[id] => 14058331
[patent_doc_number] => 10233449
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-19
[patent_title] => Methods and compositions for selecting siRNA of improved functionality
[patent_app_type] => utility
[patent_app_number] => 15/705650
[patent_app_country] => US
[patent_app_date] => 2017-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 43
[patent_no_of_words] => 31368
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705650
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/705650 | Methods and compositions for selecting siRNA of improved functionality | Sep 14, 2017 | Issued |
Array
(
[id] => 14653391
[patent_doc_number] => 20190233824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-01
[patent_title] => PD-1 SPECIFIC APTAMERS
[patent_app_type] => utility
[patent_app_number] => 16/330813
[patent_app_country] => US
[patent_app_date] => 2017-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330813
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/330813 | PD-1 SPECIFIC APTAMERS | Sep 5, 2017 | Abandoned |
Array
(
[id] => 13885509
[patent_doc_number] => 10195286
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-05
[patent_title] => Compounds and methods for trans-membrane delivery of molecules
[patent_app_type] => utility
[patent_app_number] => 15/691821
[patent_app_country] => US
[patent_app_date] => 2017-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 13
[patent_no_of_words] => 23113
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15691821
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/691821 | Compounds and methods for trans-membrane delivery of molecules | Aug 30, 2017 | Issued |
Array
(
[id] => 13805151
[patent_doc_number] => 10179837
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-01-15
[patent_title] => Dendronized polymers for nucleic acid delivery
[patent_app_type] => utility
[patent_app_number] => 15/688718
[patent_app_country] => US
[patent_app_date] => 2017-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 25
[patent_no_of_words] => 15259
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15688718
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/688718 | Dendronized polymers for nucleic acid delivery | Aug 27, 2017 | Issued |
| 15/679192 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aug 16, 2017 | Abandoned |
Array
(
[id] => 14534467
[patent_doc_number] => 20190202855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => POLYNUCLEOTIDE CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 16/326542
[patent_app_country] => US
[patent_app_date] => 2017-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -102
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326542
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/326542 | Polynucleotide constructs | Aug 16, 2017 | Issued |
Array
(
[id] => 12092801
[patent_doc_number] => 20170349895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-07
[patent_title] => 'NUCLEASE-RESISTANT DNA ANALOGUES'
[patent_app_type] => utility
[patent_app_number] => 15/678551
[patent_app_country] => US
[patent_app_date] => 2017-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 8477
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15678551
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/678551 | NUCLEASE-RESISTANT DNA ANALOGUES | Aug 15, 2017 | Abandoned |
Array
(
[id] => 15083419
[patent_doc_number] => 20190336520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => USE OF A SIRNA FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/345586
[patent_app_country] => US
[patent_app_date] => 2017-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17626
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/345586 | USE OF A SIRNA FOR TREATING CANCER | Aug 7, 2017 | Abandoned |
Array
(
[id] => 17988851
[patent_doc_number] => 20220354888
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/322000
[patent_app_country] => US
[patent_app_date] => 2017-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322000
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/322000 | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS | Aug 2, 2017 | Abandoned |
Array
(
[id] => 14342915
[patent_doc_number] => 20190153430
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => METHOD FOR GENOME EDITING
[patent_app_type] => utility
[patent_app_number] => 16/322924
[patent_app_country] => US
[patent_app_date] => 2017-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322924
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/322924 | METHOD FOR GENOME EDITING | Aug 1, 2017 | Abandoned |